CCND1 and plasma cell myeloma: Furthermore, a research group from the Mayo clinic (USA) identified kinetin riboside from a chemical library screen as the suppressor of cyclin D1 and D2 (CCND1 and CCND2) expression, showing that kinetin riboside could potentially act as a therapeutic agent for multiple myeloma [75].